Monday, August 24, 2026
60 articles analyzed
Updated Aug 24, 10:42 AM · 60 sources analyzed
Key Takeaways
Viridian Therapeutics completed three Phase 3 thyroid eye disease studies simultaneously — efficacy data disclosure is the next critical catalyst for the stock.
AbbVie's emraclidine extension study formally terminated, closing the chapter on a failed schizophrenia bet and leaving the Cerevel acquisition rationale thinner.
FDA's forthcoming generative AI device guidance will materially reshape digital health regulatory timelines and commercial strategies across the sector in 2026-2027.
🏆 Winner
Moderna — STAT News inside account reinforces the mRNA cancer vaccine program's narrative strength and strategic coherence ahead of pivotal Phase 3 readouts.
📉 Loser
AbbVie — formal termination of the emraclidine extension study confirms the failure of a centerpiece neuroscience acquisition with no near-term replacement in schizophrenia.
🔭 Watch Next
Viridian Therapeutics is expected to disclose efficacy and safety data from three completed Phase 3 veligrotug studies in thyroid eye disease — most likely at a major endocrinology or ophthalmology conference in late 2026 — which will determine whether the company can challenge Amgen's entrenched teprotumumab franchise.
Moderna-Merck cancer vaccine story gets inside treatment
STAT News published an inside account of how Moderna and Merck's mRNA-based personalized cancer vaccine program advanced from mid-stage promise to what the companies have described as a clinical success, detailing the internal strategy decisions that shaped the program. The story underscores how mRNA platform technology, originally validated by COVID-19, is now being actively redirected toward oncology — a market worth tens of billions if efficacy holds in larger trials. For the broader biotech sector, this narrative cements investor appetite for mRNA oncology plays and puts pressure on competitors developing neoantigen or tumor vaccine approaches to demonstrate comparable or superior data.
STAT News ↗Moderna-Merck mRNA cancer vaccine: inside account reveals strategic inflection moments
A STAT News report provides an inside narrative of how Moderna and Merck's personalized mRNA cancer vaccine program navigated from Phase 2 melanoma data through internal strategic debates, revealing key decision points that shaped the program's continued development.
Why it matters
For investors tracking the mRNA oncology space, the Moderna-Merck collaboration is the clearest proof-of-concept that individualized cancer vaccines can reach late-stage development at scale; the strategic and operational details in this account will matter to competitors (BioNTech, Neon Therapeutics-affiliated programs, Gritstone) who are trying to replicate or differentiate from this model. The commercial implications depend entirely on Phase 3 melanoma and lung cancer readouts expected over the next 12–18 months.
What to watch
Watch for Phase 3 data from the mRNA-4157/V940 program in melanoma and non-small cell lung cancer, with key readouts anticipated in 2026-2027 that will determine whether this program supports a regulatory filing.
Viridian Therapeutics
Veligrotug (VRDN-001) in Thyroid Eye Disease (TED)
Three separate Phase 3 studies of veligrotug in thyroid eye disease — NCT06021054 (chronic TED efficacy and safety), NCT06384547 (safety and tolerability), and NCT06179875 (open-label extension for non-responders) — have all been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in these registry updates; full numerical results have not yet been disclosed.
Why it matters
Three concurrent Phase 3 completions in TED represent a significant volume of data now in Viridian's hands — the investment thesis hinges entirely on what those numbers show when disclosed. The company's ability to carve out share from the established teprotumumab franchise depends on demonstrating meaningful differentiation in efficacy or tolerability, not just non-inferiority.
What to watch
Watch for Viridian's formal data disclosure from the completed Phase 3 studies, most likely at a major endocrinology or ophthalmology meeting in late 2026 or via a regulatory filing update.
Immunovant Sciences
Batoclimab in Graves' Disease
A proof-of-concept Phase 2 study (NCT05907668) evaluating batoclimab — an anti-FcRn antibody that reduces pathogenic IgG antibodies — over 24 weeks in adults with Graves' disease who failed antithyroid drug therapy has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in this registry update.
Why it matters
Batoclimab's mechanism — lowering IgG autoantibody titers via FcRn blockade — is biologically well-suited to Graves' disease, where TSH receptor antibodies drive pathology. Whether the trial completion translates into a pivotal program depends on the magnitude of TSH receptor antibody reduction and thyroid hormone normalization seen, data investors will need before updating any pipeline valuation.
What to watch
Watch for Immunovant to present batoclimab Graves' disease proof-of-concept data at a thyroid or immunology conference in late 2026, which would clarify whether this indication enters a formal development plan.
Eli Lilly and Company (DICE Therapeutics)
LY4100511 (DC-853) in Moderate-to-Severe Plaque Psoriasis
A Phase 2 study (NCT06602219) of LY4100511, an oral IL-17 receptor modulator developed by DICE Therapeutics (acquired by Lilly in 2023), in adults with moderate-to-severe plaque psoriasis has been marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released in this registry update.
Why it matters
Lilly paid approximately $2.4 billion for DICE specifically to access its oral biologic platform, so Phase 2 completion here is a key internal milestone; the investment thesis for the DICE acquisition rests heavily on whether DC-853's oral route translates into competitive PASI (psoriasis area severity index) scores versus established injectables. Absence of disclosed data at this stage is not unusual, but investors will want to see whether Lilly moves quickly to Phase 3 or quietly shelves the asset.
What to watch
Watch for Lilly to present LY4100511 Phase 2 efficacy data at the American Academy of Dermatology or EADV meeting in 2026-2027, which will determine whether a Phase 3 program is initiated.
Three separate Phase 3 studies of veligrotug in thyroid eye disease — NCT06021054 (chronic TED efficacy and safety), NCT06384547 (safety and tolerability), and NCT06179875 (open-label extension for non-responders) — have all been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in these registry updates; full numerical results have not yet been disclosed.
Why it matters
Viridian is building a dense dataset across active and chronic TED populations, putting it in direct competition with Amgen's tepetekimab and Horizon's teprotumumab (now Amgen) in a market where differentiation on speed of response and subpopulation breadth will matter.
Analysis
Three concurrent Phase 3 completions in TED represent a significant volume of data now in Viridian's hands — the investment thesis hinges entirely on what those numbers show when disclosed. The company's ability to carve out share from the established teprotumumab franchise depends on demonstrating meaningful differentiation in efficacy or tolerability, not just non-inferiority.
What to watch
Watch for Viridian's formal data disclosure from the completed Phase 3 studies, most likely at a major endocrinology or ophthalmology meeting in late 2026 or via a regulatory filing update.
A proof-of-concept Phase 2 study (NCT05907668) evaluating batoclimab — an anti-FcRn antibody that reduces pathogenic IgG antibodies — over 24 weeks in adults with Graves' disease who failed antithyroid drug therapy has been marked Completed on ClinicalTrials.gov. No efficacy or safety outcome data have been released in this registry update.
Why it matters
Graves' disease is an underserved thyroid autoimmune market, and a successful proof-of-concept here could expand batoclimab's label ambitions well beyond its current myasthenia gravis and CIDP programs.
Analysis
Batoclimab's mechanism — lowering IgG autoantibody titers via FcRn blockade — is biologically well-suited to Graves' disease, where TSH receptor antibodies drive pathology. Whether the trial completion translates into a pivotal program depends on the magnitude of TSH receptor antibody reduction and thyroid hormone normalization seen, data investors will need before updating any pipeline valuation.
What to watch
Watch for Immunovant to present batoclimab Graves' disease proof-of-concept data at a thyroid or immunology conference in late 2026, which would clarify whether this indication enters a formal development plan.
A Phase 2 study (NCT06602219) of LY4100511, an oral IL-17 receptor modulator developed by DICE Therapeutics (acquired by Lilly in 2023), in adults with moderate-to-severe plaque psoriasis has been marked Completed on ClinicalTrials.gov. No efficacy or safety data have been released in this registry update.
Why it matters
Oral IL-17 inhibition is a high-value target in psoriasis — if LY4100511 shows meaningful skin clearance, it would give Lilly a potential oral competitor to its own injectable IL-17 antibodies and to competitors like UCB's bimekizumab.
Analysis
Lilly paid approximately $2.4 billion for DICE specifically to access its oral biologic platform, so Phase 2 completion here is a key internal milestone; the investment thesis for the DICE acquisition rests heavily on whether DC-853's oral route translates into competitive PASI (psoriasis area severity index) scores versus established injectables. Absence of disclosed data at this stage is not unusual, but investors will want to see whether Lilly moves quickly to Phase 3 or quietly shelves the asset.
What to watch
Watch for Lilly to present LY4100511 Phase 2 efficacy data at the American Academy of Dermatology or EADV meeting in 2026-2027, which will determine whether a Phase 3 program is initiated.
A long-term safety and tolerability extension study (NCT05443724) of emraclidine — a selective M4 muscarinic receptor agonist for schizophrenia that AbbVie acquired via its Cerevel Therapeutics purchase — has been marked Terminated on ClinicalTrials.gov. No efficacy or safety outcome data from this termination have been disclosed in the registry update; this follows broader public knowledge that emraclidine failed its Phase 2 EMPOWER trials in 2024.
Why it matters
Emraclidine was one of the most closely watched next-generation antipsychotic candidates; its failure and now formal study termination narrows the field of muscarinic-mechanism schizophrenia drugs and removes a key part of the strategic rationale for AbbVie's $8.7 billion Cerevel acquisition.
Analysis
The termination of this extension study is a formality that closes the chapter on emraclidine — the real damage to AbbVie's neuroscience pipeline was done when EMPOWER failed in 2024. The question now is whether Karuna's KarXT (now Bristol Myers Squibb's Cobenfy, the approved M1/M4 agonist) remains the only viable muscarinic entry in schizophrenia, or whether other pipeline assets can fill the void AbbVie is left with.
What to watch
Watch for AbbVie's next neuroscience pipeline update — likely at a 2026 investor day or R&D presentation — to clarify what, if anything, replaces emraclidine as the company's schizophrenia franchise anchor.
A dose-ranging Phase 2 prophylaxis study (NCT05047185) of oral PHA-022121, a bradykinin B2 receptor antagonist, in patients with hereditary angioedema (HAE) Types I and II has been marked Terminated on ClinicalTrials.gov. No outcome data or formal reason for termination are disclosed in this registry update.
Why it matters
Pharvaris had been positioning PHA-022121 as both an on-demand and prophylaxis oral option in HAE, a market dominated by subcutaneous and intravenous agents from Takeda, BioCryst, and KalVista — a termination of the prophylaxis arm, if confirmed, meaningfully narrows the commercial story.
Analysis
HAE is a market where ease of administration is the key differentiator, and Pharvaris's oral route was its core competitive argument; if the prophylaxis program is curtailed, the company's value proposition depends much more heavily on the on-demand treatment data, which is a smaller and more competitive market segment. Investors should look for a formal company statement clarifying the scope of the termination before drawing conclusions about the full program.
What to watch
Watch for a formal Pharvaris press release or investor update clarifying whether the termination reflects strategic repositioning or a safety or efficacy signal from the dose-ranging data.
FDA
FDA's digital health leader Rick Abramson signals that generative AI regulatory guidance documents for medical devices are in development and will be released, per STAT News.
Why it matters
Companies building AI-enabled diagnostics, software as a medical device, or AI-assisted clinical decision tools are operating without a clear regulatory framework — forthcoming FDA guidance will either accelerate or constrain product development timelines and 510(k)/De Novo submission strategies.
Analysis
The absence of generative AI device guidance has created regulatory uncertainty that is holding back commercial launches and investor commitments in the digital health sector; a formal FDA framework, even a draft, would likely be a net positive for companies that have been waiting to file. The key question is whether guidance will treat generative AI outputs as a new device category requiring clinical validation, or apply existing software as a medical device frameworks with modifications.
What to watch
Watch for FDA to publish a draft guidance document on generative AI in medical devices — likely in late 2026 or early 2027 — which will set the parameters for submission requirements and post-market surveillance expectations.
Small molecule blocks CD28 costimulation selectively in IBD — sparing CTLA-4 pathway
A bioRxiv preprint from 2026-08-24 reports that researchers used a NanoBiT split-luciferase screening platform to identify a small molecule that selectively inhibits CD28 costimulation (the signal that activates T cells) in inflammatory bowel disease models, without disrupting CTLA-4 signaling — a limitation of current B7-directed biologics like abatacept.
Why it matters
A CD28-selective oral small molecule could offer a cleaner immunosuppressive profile than existing T cell costimulation blockers, potentially improving the benefit-risk ratio in IBD and other autoimmune conditions without the immune checkpoint complications seen with broad B7 blockade.
Analysis
This is early-stage chemistry, but the selectivity claim — preserving CTLA-4 while blocking CD28 — is exactly what immunology drug developers have been trying to achieve to avoid the immunosuppression-versus-regulation tradeoff inherent in abatacept and belatacept. Companies with active IBD small molecule programs (e.g., AbbVie, Pfizer, Roivant subsidiaries) and platform investors in costimulation biology should track whether this scaffold advances toward IND-enabling studies.
What to watch
Watch for this group to submit a peer-reviewed publication and initiate preclinical toxicology studies — the key gate before any IND filing timeline becomes discussable.
Cryo-EM maps eight TOP1 poison drugs at atomic resolution — opens resistance and combo design
A bioRxiv preprint reports cryo-EM (high-resolution electron microscopy) structural analysis of human topoisomerase 1 (TOP1) trapped by eight approved anticancer drugs, revealing the precise molecular interactions that stabilize the TOP1-DNA complex and block DNA repair — the mechanism of cell killing for camptothecin-class drugs including irinotecan and topotecan.
Why it matters
Atomic-resolution maps of how each drug traps TOP1 provide a rational basis for designing next-generation TOP1 poisons with improved selectivity, reduced off-target toxicity, or activity against resistance mutations — highly relevant for the growing class of antibody-drug conjugates (ADCs) that use camptothecin payloads, including AstraZeneca and Daiichi's trastuzumab deruxtecan.
Analysis
ADC developers using TOP1 poison payloads — a now-crowded field spanning breast, lung, and colorectal oncology — will find this structural dataset useful for payload optimization and for understanding why some tumors develop resistance to deruxtecan-class ADCs. Any company with a TOP1 payload ADC in early development should be monitoring this preprint for competitive intelligence on next-generation payload design.
What to watch
Watch for peer-reviewed publication and whether any structural biology or ADC-focused company files patents or IND applications referencing this structural scaffold within the next 12–18 months.
Moderna-Merck mRNA cancer vaccine: inside account reveals strategic inflection moments
A STAT News report provides an inside narrative of how Moderna and Merck's personalized mRNA cancer vaccine program navigated from Phase 2 melanoma data through internal strategic debates, revealing key decision points that shaped the program's continued development.
Why it matters
The account illustrates how personalized neoantigen vaccine manufacturing — historically a bottleneck for individualized cancer immunotherapy — was de-risked using mRNA platform infrastructure, and how the companies structured a co-development agreement that survived significant internal skepticism.
Analysis
For investors tracking the mRNA oncology space, the Moderna-Merck collaboration is the clearest proof-of-concept that individualized cancer vaccines can reach late-stage development at scale; the strategic and operational details in this account will matter to competitors (BioNTech, Neon Therapeutics-affiliated programs, Gritstone) who are trying to replicate or differentiate from this model. The commercial implications depend entirely on Phase 3 melanoma and lung cancer readouts expected over the next 12–18 months.
What to watch
Watch for Phase 3 data from the mRNA-4157/V940 program in melanoma and non-small cell lung cancer, with key readouts anticipated in 2026-2027 that will determine whether this program supports a regulatory filing.
The Trump administration is advancing a Medicaid rule that would deny coverage for gender-affirming drugs using a novel legal approach, with STAT News reporting the precedent could be extended to restrict Medicaid coverage of other drug classes.
Why it matters
Any company with products used in populations heavily reliant on Medicaid coverage — not just gender-affirming care — faces potential commercial exposure if this coverage-restriction mechanism is applied more broadly, creating downstream reimbursement risk across therapeutic areas.
Analysis
This is a systemic coverage policy risk more than a single-drug event: if the administration establishes a legal pathway to deny Medicaid drug coverage on categorical grounds, the commercial models of companies selling drugs in any politically contested therapeutic area — from reproductive health to addiction medicine — need to account for coverage uncertainty in Medicaid patient populations. Investors modeling Medicaid-exposed revenue should flag this as a developing policy risk rather than an isolated development.
What to watch
Watch for legal challenges to this Medicaid rule and CMS guidance clarifying the scope of the coverage restriction mechanism, which will determine how broadly it can be applied beyond gender-affirming drugs.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.
Every weekday morning
Start your morning with the stories moving biotech.
Clinical readouts · FDA watch · Deal flow · Pipeline pulse